Results 41 to 50 of about 32,676 (224)
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Port catheters provide a reliable, long‐term venous access option in children for repeated administration of medications or parenteral nutrition. A cardiac catheterization procedure was performed in a 7‐year‐old girl in whom lateral chest radiography revealed posterior deviation suggestive of azygos vein malposition.
Axel Rentzsch +3 more
wiley +1 more source
Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation
CJC Open, 2021 Rivaroxaban is commonly used for prevention of thromboembolic diseases in patients with atrial fibrillation. We report a case of an 86-year-old man with hypertension, chronic kidney disease, type 2 diabetes mellitus, dyslipidemia, and atrial fibrillation
Jiaming (Calvin) Liang, MD, MSc +3 more
doaj +1 more source
Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases [PDF]
, 2016 In the therapeutic approach to patients with antiphospholipid syndrome (APS) with thrombotic manifestations, oral vitamin K antagonists (VKA) remain the standard of care.
Marzena Olesińska, Ewa Haładyj
core +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Aortic stenosis (AS) is associated with a heightened burden of cardiovascular comorbidities, atrial fibrillation (AF), and progressive valvular calcification, all of which may contribute to cerebrovascular events across the disease continuum.
Priyanka Boettger +7 more
wiley +1 more source
BMC Cardiovascular Disorders, 2017 Background Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).
Faye L. Norby +7 more
doaj +1 more source
A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation
Clinical Pharmacology &Therapeutics, EarlyView.The novel application of Virtual Twins (VT) in PBPK (VT‐PBPK) presents the opportunity to advance precision dosing and accelerate the shift from one‐size‐fits‐all to targeted, individualized treatments. This review aims to: (1) critically evaluate existing research on the use of VTs in PBPK, (2) develop a conceptual definition of VT‐PBPK, (3) describe ...
Emily Mannix +4 more
wiley +1 more source
, 2021 AIMS To investigate the influence of a cytochrome P450 CYP3A4 and efflux transporter P-glycoprotein (P-gp) inducing Hypericum perforatum extract on the pharmacokinetics and pharmacodynamics of rivaroxaban.
Urs Duthaler +15 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Personalized dosing is particularly important for drugs with narrow therapeutic indices in geriatric patients, who exhibit substantial physiological variability and limited pharmacokinetic (PK) evidence to guide individualized dose selection. Valproic acid (VPA) is an effective treatment option for bipolar disorder in older adults, yet dosing largely ...
Yoo Jin Jang +2 more
wiley +1 more source
TH Open, 2018 Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim +7 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source